Table 5.
Asthma treatments in the 12 months prior to study enrollment
| Total participants (N = 101) | |
|---|---|
| Chronic OCS, no/yes | 94 (93)/7 (7) |
| Chronic OCS treatment ( N = 7)* | |
| Prednisone | 7 (100%) |
| Total daily dose, mg | 10.7 ± 6.7 |
| Total exposure (12 months), mg | 3679.3 ± 2703.1 |
| CS burst treatment†, no/yes | 40 (40%)/60 (60%) |
| Active substance (N = 59)*,† | |
| Hydrocortisone | 1 (2%) |
| Methylprednisolone | 3 (5%) |
| Prednisone | 55 (93%) |
| Total number (12 months) (N = 60)* | |
| 1 | 13 (22%) |
| 2 | 20 (33%) |
| 3 | 10 (17%) |
| > 3 | 17 (28%) |
| ICS/LABA (fixed dose combination), no/yes | 2 (2%)/99 (98%) |
| Active substance ( N = 99)* | |
| Beclomethasone/formoterol | 1 (1%) |
| Budesonide/formoterol | 52 (53%) |
| Fluticasone/salmeterol | 44 (44%) |
| Fluticasone/vilanterol | 2 (2%) |
| Total daily dose (N = 99)*,‡ | |
| Low dose | 2 (2%) |
| Medium dose | 50 (51%) |
| High dose | 47 (47%) |
Data are shown as n (%) or mean ± SD
CS corticosteroid, ICS inhaled corticosteroid, LABA long-acting beta-agonist, OCS oral corticosteroid, SD standard deviation
*Treatment information is given for the patients who answered Yes to the corresponding question about treatment
†Information was missing for one patient
‡Low, medium, and high dose was defined according to the Global Asthma Report 2018 [1]